<DOC>
	<DOCNO>NCT00828919</DOCNO>
	<brief_summary>To allow continuation treatment patient experience benefit AG 013736</brief_summary>
	<brief_title>Continuing Access To AG- 013736 ( A406 ) For Patients Previously Receiving AG 013736 In Clinical Trials</brief_title>
	<detailed_description />
	<mesh_term>Axitinib</mesh_term>
	<criteria>Patients assign axitinib contain treatment arm previous clinical trial Patients receive axitinib tablet time previous trial end Patients stable ( SD ) respond disease ( PR CR ) document appropriate radiological , clinical , laboratory assessment within 12 week enrollment ( Note : response criterion previous AG013736 protocol use determine stable respond disease ) . Patients progressive disease ( PD ) experience `` clinical benefit '' define study protocol Patients may participate trial condition continue treatment previous AG013736 protocol meet</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>VEGFR inhibitor</keyword>
	<keyword>angi-angiogenic</keyword>
	<keyword>tyrosine kinase inhibitor</keyword>
</DOC>